Aclaris Therapeutics, Inc. (NasdaqGS:ACRS) announced that it is conducting a strategic review of its business to determine how to optimally deploy its capital to maximize shareholder return. On a preliminary unaudited basis, as of December 31, 2023, Aclaris? aggregate cash, cash equivalents and marketable securities was approximately $182 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | +4.76% |
|
+10.00% | +25.71% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.71% | 94.07M | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- ACRS Stock
- News Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Conducts Strategic Review of Business